A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

Philip Raskin, Marc Rendell, Matthew C. Riddle, Jo F. Dole, Martin I. Freed, Julio Rosenstock

Research output: Contribution to journalArticle

281 Citations (Scopus)

Abstract

OBJECTIVE- To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy. RESEARCH DESIGN AND METHODS- After 8 weeks of insulin standardization and placebo (PBO) run-in, 319 type 2 diabetic patients with mean baseline HbA1c ≥ 7.5% (8.9 ± 1.1 to 9.1 ± 1.3) on twice-daily insulin therapy (total daily dose ≥30 U) were randomized to 26 weeks of additional treatment with RSG (4 or 8 mg daily) or PBO. Insulin dose could be downtitrated only for safety reasons. The primary end point was reduction of HbA1c from baseline. RESULTS- RSG 4 and 8 mg daily significantly improved glycemic control, which was unchanged on PBO. By intent-to-treat analysis, treatment with RSG 8 mg plus insulin resulted in a mean reduction from baseline in HbA1c of 1.2% (P <0.0001), despite a 12% mean reduction of insulin dosage. Over 50% of subjects treated daily with RSG 8 mg plus insulin had a reduction of HbA1c ≥ 1.0%. Neither total:HDL cholesterol nor LDL:HDL cholesterol ratios significantly changed with RSG treatment. Serious adverse events did not differ among groups. CONCLUSIONS- The addition of RSG to insulin treatment results in significant improvement in glycemic control and is generally well tolerated.

Original languageEnglish
Pages (from-to)1226-1232
Number of pages7
JournalDiabetes Care
Volume24
Issue number7
StatePublished - 2001

Fingerprint

rosiglitazone
Type 2 Diabetes Mellitus
Insulin
Therapeutics
Placebos
HDL Cholesterol
Safety

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Raskin, P., Rendell, M., Riddle, M. C., Dole, J. F., Freed, M. I., & Rosenstock, J. (2001). A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care, 24(7), 1226-1232.

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. / Raskin, Philip; Rendell, Marc; Riddle, Matthew C.; Dole, Jo F.; Freed, Martin I.; Rosenstock, Julio.

In: Diabetes Care, Vol. 24, No. 7, 2001, p. 1226-1232.

Research output: Contribution to journalArticle

Raskin, P, Rendell, M, Riddle, MC, Dole, JF, Freed, MI & Rosenstock, J 2001, 'A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes', Diabetes Care, vol. 24, no. 7, pp. 1226-1232.
Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226-1232.
Raskin, Philip ; Rendell, Marc ; Riddle, Matthew C. ; Dole, Jo F. ; Freed, Martin I. ; Rosenstock, Julio. / A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. In: Diabetes Care. 2001 ; Vol. 24, No. 7. pp. 1226-1232.
@article{f54edf22d232494394f85b71851a7ccf,
title = "A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes",
abstract = "OBJECTIVE- To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy. RESEARCH DESIGN AND METHODS- After 8 weeks of insulin standardization and placebo (PBO) run-in, 319 type 2 diabetic patients with mean baseline HbA1c ≥ 7.5{\%} (8.9 ± 1.1 to 9.1 ± 1.3) on twice-daily insulin therapy (total daily dose ≥30 U) were randomized to 26 weeks of additional treatment with RSG (4 or 8 mg daily) or PBO. Insulin dose could be downtitrated only for safety reasons. The primary end point was reduction of HbA1c from baseline. RESULTS- RSG 4 and 8 mg daily significantly improved glycemic control, which was unchanged on PBO. By intent-to-treat analysis, treatment with RSG 8 mg plus insulin resulted in a mean reduction from baseline in HbA1c of 1.2{\%} (P <0.0001), despite a 12{\%} mean reduction of insulin dosage. Over 50{\%} of subjects treated daily with RSG 8 mg plus insulin had a reduction of HbA1c ≥ 1.0{\%}. Neither total:HDL cholesterol nor LDL:HDL cholesterol ratios significantly changed with RSG treatment. Serious adverse events did not differ among groups. CONCLUSIONS- The addition of RSG to insulin treatment results in significant improvement in glycemic control and is generally well tolerated.",
author = "Philip Raskin and Marc Rendell and Riddle, {Matthew C.} and Dole, {Jo F.} and Freed, {Martin I.} and Julio Rosenstock",
year = "2001",
language = "English",
volume = "24",
pages = "1226--1232",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

AU - Raskin, Philip

AU - Rendell, Marc

AU - Riddle, Matthew C.

AU - Dole, Jo F.

AU - Freed, Martin I.

AU - Rosenstock, Julio

PY - 2001

Y1 - 2001

N2 - OBJECTIVE- To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy. RESEARCH DESIGN AND METHODS- After 8 weeks of insulin standardization and placebo (PBO) run-in, 319 type 2 diabetic patients with mean baseline HbA1c ≥ 7.5% (8.9 ± 1.1 to 9.1 ± 1.3) on twice-daily insulin therapy (total daily dose ≥30 U) were randomized to 26 weeks of additional treatment with RSG (4 or 8 mg daily) or PBO. Insulin dose could be downtitrated only for safety reasons. The primary end point was reduction of HbA1c from baseline. RESULTS- RSG 4 and 8 mg daily significantly improved glycemic control, which was unchanged on PBO. By intent-to-treat analysis, treatment with RSG 8 mg plus insulin resulted in a mean reduction from baseline in HbA1c of 1.2% (P <0.0001), despite a 12% mean reduction of insulin dosage. Over 50% of subjects treated daily with RSG 8 mg plus insulin had a reduction of HbA1c ≥ 1.0%. Neither total:HDL cholesterol nor LDL:HDL cholesterol ratios significantly changed with RSG treatment. Serious adverse events did not differ among groups. CONCLUSIONS- The addition of RSG to insulin treatment results in significant improvement in glycemic control and is generally well tolerated.

AB - OBJECTIVE- To determine the efficacy and safety of rosiglitazone (RSG) when added to insulin in the treatment of type 2 diabetic patients who are inadequately controlled on insulin monotherapy. RESEARCH DESIGN AND METHODS- After 8 weeks of insulin standardization and placebo (PBO) run-in, 319 type 2 diabetic patients with mean baseline HbA1c ≥ 7.5% (8.9 ± 1.1 to 9.1 ± 1.3) on twice-daily insulin therapy (total daily dose ≥30 U) were randomized to 26 weeks of additional treatment with RSG (4 or 8 mg daily) or PBO. Insulin dose could be downtitrated only for safety reasons. The primary end point was reduction of HbA1c from baseline. RESULTS- RSG 4 and 8 mg daily significantly improved glycemic control, which was unchanged on PBO. By intent-to-treat analysis, treatment with RSG 8 mg plus insulin resulted in a mean reduction from baseline in HbA1c of 1.2% (P <0.0001), despite a 12% mean reduction of insulin dosage. Over 50% of subjects treated daily with RSG 8 mg plus insulin had a reduction of HbA1c ≥ 1.0%. Neither total:HDL cholesterol nor LDL:HDL cholesterol ratios significantly changed with RSG treatment. Serious adverse events did not differ among groups. CONCLUSIONS- The addition of RSG to insulin treatment results in significant improvement in glycemic control and is generally well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0035408779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035408779&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 1226

EP - 1232

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 7

ER -